296 related articles for article (PubMed ID: 32468091)
1. [Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
Kramer MW; Gakis G
Urologe A; 2020 Jul; 59(7):784-789. PubMed ID: 32468091
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
3. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
4. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
[TBL] [Abstract][Full Text] [Related]
6. Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
Med Hypotheses; 2016 Jul; 92():57-8. PubMed ID: 27241256
[TBL] [Abstract][Full Text] [Related]
7. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
8. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
10. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
11. Immune therapies in non-muscle invasive bladder cancer.
Ho PL; Williams SB; Kamat AM
Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
[TBL] [Abstract][Full Text] [Related]
12. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Mukherjee N; Svatek RS; Mansour AM
Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
Loriot Y; Rouprêt M
Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
16. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
[TBL] [Abstract][Full Text] [Related]
17. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
[TBL] [Abstract][Full Text] [Related]
18. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
19. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].
Leucht K; Foller S; Grimm MO
Urologe A; 2021 Nov; 60(11):1400-1408. PubMed ID: 34709440
[TBL] [Abstract][Full Text] [Related]
20. Update on the guideline of guidelines: non-muscle-invasive bladder cancer.
Taylor J; Becher E; Steinberg GD
BJU Int; 2020 Feb; 125(2):197-205. PubMed ID: 31597003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
